We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Fecal Occult Blood Screening Increases High-Risk Polyp Detection

By LabMedica International staff writers
Posted on 12 Jan 2015
The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk precancerous adenomas, sometimes called polyps, by 89%.

As part of the screening program, a prescreening procedure is undertaken by a general practitioner or gastroenterologist to identify patients who are at higher than average risk of colorectal cancer based on their family history and those patients were invited to undergo colonoscopy rather than fecal occult blood test (FOBT).

Scientists at the University of Burgundy (INSERM Unité 866; Dijon, France) evaluate the rate of diagnosis of adenomas before and after the initiation of a screening program using fecal occult blood testing that began in 2003. More...
The study included all residents aged between 50 and 74 years of age who had a first adenoma identified between January 1997 and December 2008. The investigators showed that 38.7% of these people had high-risk adenomas, meaning they were larger than one centimeter in diameter, involved the finger-like projections called villi in the intestinal lining, or exhibited a high grade of dysplasia.

Of 1,179 patients studied, 889 underwent colonoscopy, and overall, 253 colorectal neoplasias were diagnosed including 35 cancers, and adenomas in 219 patients. A total of 209 advanced adenomas were diagnosed. The authors calculated that the positive predictive value of colonoscopy was 3.9% for cancer, 12.9% for advanced adenoma, and 25% for adenoma overall. This compared poorly to the positive predictive value in the average risk population selected by a positive FOBT. In this population, the positive predictive value of the colonoscopy done after positive test in their administrative area ranges from 7.5% to 10% for cancer, from 15% to 27% for advanced adenoma and between 32% and 37% for adenoma. The immunochemical fecal occult blood tests outperformed guaiac tests for the detection of colorectal cancer and advanced adenoma. They have doubled the detection rate of invasive colorectal cancer, mostly at early stages, and led to a fourfold increase in the detection rate of noninvasive colorectal cancer and advanced adenomas.

Hans-Joachim Schmoll, MD, PhD, a professor of Hematology and Oncology, at the Martin Luther University Halle-Wittenberg (Halle, Germany) said, “In this study it was shown that a prediction for screening colonoscopy using high risk features—based on family history—revealed a less positive predictive value than prescreening by FOBT with follow-up of those who have a positive result.” The study was presented at the European Society for Medical Oncology Congress held September 26–30, 2014, in Madrid (Spain).

Related Links:

University of Burgundy 
Martin Luther University Halle-Wittenberg



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.